Memorial Sloan Kettering to offer Dignicap® scalp cooling device in New York metro area locations

Dignitana AB, a world leader in medical scalp-cooling technology, announced today that the DigniCap® scalp cooling system, which was cleared in December 2015 by the U.S. FDA to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, will be available at all Memorial Sloan Kettering Cancer Center (MSK) facilities that treat breast cancer.

The DigniCap® system is the first and only scalp-cooling device to receive FDA clearance. In the rigorous FDA clinical trial, seven out of ten patients with early-stage breast cancer kept at least 50% of their hair. The demand for the FDA-cleared DigniCap® system has been significant this year in the United States.

MSK, a world leader in cancer patient care, research, and educational programs, will now have the 17 units ordered in December of 2016 available for use by female patients undergoing breast cancer treatment in eight of their outpatient facilities in the New York City area. These include MSK Basking Ridge and MSK Monmouth, in New Jersey; MSK Westchester, in Westchester County, New York; and MSK Commack and MSK Rockville Centre, on Long Island, in addition to their Manhattan and Brooklyn locations.

"Scalp cooling is clinically proven and can be an important tool for many women in treatment for breast cancer," says Mario Lacouture, MD, Director of the Oncodermatology Program at MSK. "As a world leader in comprehensive cancer care, we are proud to be able to offer our patients across the New York metro area this new FDA-cleared advancement that addresses one of the most distressing and most visible side effects of chemotherapy."

"Bringing the DigniCap® system to MSK is an important milestone for Dignitana," says William Cronin, Chief Executive Officer of Dignitana, Inc., the U.S. subsidiary of Dignitana AB. "We have just passed the one-year anniversary of clearance by the FDA for DigniCap® in the U.S., and we are proud to add Memorial Sloan Kettering, one of the top comprehensive cancer centers in the U.S., to the growing number of facilities that are providing this treatment option to patients on a large scale."

The DigniCap® clinical team is working directly with the clinical practitioners at each of the eight MSK sites to train and certify staff on the machine.  This is the largest scalp-cooling installation at any medical center to date in the U.S. Nearly 100 nurses and other medical personnel will be trained in preparation for the launch of this service at MSK in the Spring of 2017.

The DigniCap® scalp cooling system features a patented tight-fitting silicone cooling cap that is placed directly on the head, and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit with touch-screen prompts. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. The cap is fitted to the head, and the temperature of the scalp is lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to decreased intra follicular metabolic rate. These factors together reduce the risk of chemotherapy-induced hair loss.

Lund, Sweden - February 13, 2017

Media Contacts:
Caren Browning
King + Company
+1 212 561-7464
Caren.Browning@kingcompr.com

Semmy Rülf
Chairman of the board
+46 (0)709 312730
semmy.rulf@dignitana.se

About Dignitana AB (publ)
Dignitana is a Swedish public company, based in Lund, and manufacturer of the medical cooling device DigniCap®. Dignitana AB is listed on the OMX Nasdaq First North stock exchange and has appointed Erik Penser Bank as Certified Advisor. Headquartered in Dallas, Texas, Dignitana, Inc. is the U.S. subsidiary of Dignitana AB. For more information visit www.dignitana.com.

About Memorial Sloan Kettering
We are the world's oldest and largest private cancer center, home to more than 14,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. As an independent institution, we combine 130 years of research and clinical leadership with the freedom to provide highly individualized, exceptional care to each patient. And our always-evolving educational programs continue to train new leaders in the field, here and around the world. For more information, go to www.mskcc.org.

Dignitana Promotes Scalp Cooling at Supportive Care Conference

Dignitana ABworld leader in clinically superior scalp cooling technology, is co-sponsoring a scalp cooling session at the Multinational Association for Supportive Care in Cancer (MASCC) Annual Meeting, held June 21 - 23 in San Francisco, California.



Kommuniké från Dignitana AB årsstämma 2019

Dignitana AB, tillverkare av Dignicap®scalp Cooling system, höll idag årsstämma i bolagets lokaler på traktorgränden 3 i Lund. Stämman beslutade i enlighet med samtliga förslag som styrelsen och aktieägare lagt fram. Nedan följer en sammanfattning av de beslut som fattats. 


Communication from the Dignitana AB Annual General Meeting 2019

Dignitana AB, manufacturer of The DigniCap® Scalp Cooling System, has today held an Annual General Meeting at the company's premises at Traktorgränden 3 in Lund. In all the proposed cases, the AGM resolved in accordance with the Board's proposal. Below is a summary of the decisions taken. 


Dignitana AB Publishes Q1 2019 Interim Report

Results and financial position

Significant events during the period

  • Sales and other income for the period amounted to 10,106 TSEK, $1,102 KUSD, an increase of 69 percent compared to the same period in 2018 and a15 percent quarter over quarter growth compared to fourth quarter 2018.
  • EBITDA amounted to (2,799) TSEK, ($305) KUSD, a 59 percent improvement compared to the same period in 2018.
  • Contracts were signed for 22 locations globally, bringing the total number of sites in the U.S. to 125 in 29 states at the close of first quarter.
  • Dignitana announced receipt of CE Marking approval for European sales of the new DigniCap Delta device.
  • As a result of the rights and directed equity issues in December, Dignitana now has 48,599,155 shares registered at Swedish Companies Registration Office.
  • Dignitana announced a partnership with oneservice GmbH, a global provider of specialty technical services, to provide service and maintenance to facilities offering DigniCap in Europe.

Dignitana Leadership Efforts Prompt Landmark Legislation

Dignitana AB (publ)manufacturer of The DigniCap® Scalp Cooling System, announces that HB3984, the bill providing coverage for scalp cooling that the company initiated in February with Texas State legislators, was passed in the Texas House of Representatives on Friday. The Bill now moves to the Senate where it will be introduced by Sen. Angela Paxton. Once passed in the Senate, the Bill then requires approval by Texas Governor Greg Abbott before being signed into law.



Kallelse till årsstämma i Dignitana AB (publ)

Aktieägarna i Dignitana AB (publ), 556730-5346("Bolaget") kallas härmed till årsstämma onsdag den 15 maj 2019 kl. 9.00 i Bolagets lokaler, Traktorgränden 3, i Lund.


Notice of Annual General Meeting of Dignitana AB (publ)

Aktieägarna i Dignitana AB (publ), 556730-5346("Bolaget") kallas härmed till årsstämma onsdag den 15 maj 2019 kl. 9.00 i Bolagets lokaler, Traktorgränden 3, i Lund.


Rättelse: Felaktig MAR-klassificering i tidigare pressmeddelande

Dignitana AB issues a rättelse i pressmeddelande "Dignitana AB publicerar årsredovisningen för 2018." Rättelsen avser att pressmeddelandet var felaktigt klassat som MAR och innehöll därför stycket som följer:


Correction: Incorrect MAR Classification in previous press release

Dignitana AB issues a correction in press release "Dignitana AB publishes the annual report for 2018." The correction means that the press release was incorrectly classified as MAR and therefore contained the paragraph as follows:


Dignitana AB publicerar årsredovisningen för 2018

Lund, Sweden - 12 April 2019 - Dignitana AB offentliggör härmed årsredovisningen avseende 2018. Årsredovisningen finns som bilaga till detta pressmeddelande samt går att ladda ner från hemsidan, www.dignitana.se. Det går även att beställa en utskriven version via investorrelations@dignitana.com.


Dignitana AB Publishes Annual Report for 2018

Lund, Sweden - 12 April 2019 - Dignitana AB hereby publishes the annual report for 2018. The Annual Report is attached to this press release and will be posted today on the Dignitana website. You can also order a printed version via investorrelations@dignitana.com.


Dignitana AB Receives CE Marking for Next Generation DigniCap Delta to Reduce Hair Loss from Chemotherapy

Dignitana AB (publ), manufacturer of The DigniCap® Scalp Cooling System, today announced receiving CE Marking approval for European sales of DigniCap Delta, the next generation scalp cooling device. An advanced and redesigned model of the 2015 FDA-cleared DigniCap Scalp Cooling System, DigniCap Delta features a new single patient use cap system consisting of a flexible Cooling Wrap and an adjustable Thermal Cap to optimize scalp cooling outcomes and ease-of-use for patients and nurses. The streamlined DigniCap Delta is 54 percent smaller than the current model and the intuitive interface provides up to 80 percent reduction in nursing time per patient infusion versus the existing device.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär